Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
decrease release » increased release (Expand Search)
larger decrease » marked decrease (Expand Search)
lower decrease » linear decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
Showing 81 - 100 results of 17,964 for search '(( significantly ((lower decrease) OR (larger decrease)) ) OR ( significant decrease release ))', query time: 0.80s Refine Results
  1. 81
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 82
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 83
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 84
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 85
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 86
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 87
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 88
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 89
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 90
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 91
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 92
    Fig 5 -

    Fig 5 - by Alireza Latifi (14593561)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 93
    Physicochemical properties of miltefosine-loaded chitosan nanoparticles.

    Physicochemical properties of miltefosine-loaded chitosan nanoparticles. by Alireza Latifi (14593561)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 94
    Comparison of cell cytotoxicity effect.

    Comparison of cell cytotoxicity effect. by Alireza Latifi (14593561)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 95
    Schematic illustration of the preparation of MF-loaded chitosan nanoparticles by ionotropic gelation method.

    Schematic illustration of the preparation of MF-loaded chitosan nanoparticles by ionotropic gelation method. by Alireza Latifi (14593561)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 96
    IC<sub>50</sub> of MF, MF-CS-NPs, CS-NPs on Trophozoites and cyst form of <i>Acanthamoeba</i> after 24 and 48 hours of drug exposure.

    IC<sub>50</sub> of MF, MF-CS-NPs, CS-NPs on Trophozoites and cyst form of <i>Acanthamoeba</i> after 24 and 48 hours of drug exposure. by Alireza Latifi (14593561)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 97
    Physical characterization of nanoparticles.

    Physical characterization of nanoparticles. by Alireza Latifi (14593561)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 98
    Microscopic images of <i>Acanthamoeba</i> after 24 h of treatment.

    Microscopic images of <i>Acanthamoeba</i> after 24 h of treatment. by Alireza Latifi (14593561)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 99
    Transmission electron microscopy (TEM) image of the MF-CS-NPs.

    Transmission electron microscopy (TEM) image of the MF-CS-NPs. by Alireza Latifi (14593561)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 100
    The in-vitro drug assay against the trophozoites and cysts of <i>Acanthamoeba</i>.

    The in-vitro drug assay against the trophozoites and cysts of <i>Acanthamoeba</i>. by Alireza Latifi (14593561)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: